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Individual Study Methods and Cohort Descriptions 
 
The cohorts contributing to this study were general population samples. All participants provided written 
informed consent and studies were approved by their local Research Ethics Committees and/or Institutional 
Review Boards.  Summary demographic characteristics are listed in Table S2.  References for 
ascertainment methods and erythrocyte trait measurement for each participating study are given below. 
 
European Ancestry Cohorts 
 
Age, Gene/Environment Susceptibility‐Reykjavik Study (AGES)1,2 
 
Atherosclerosis Risk in Communities Study (ARIC)2,3 
 
Austrian Stroke Prevention Study  (ASPS) 4 
 
Baltimore Longitudinal Study of Aging (BLSA)5 
 
Coronary Artery Risk Development in Young Adults  (CARDIA)6 
 
Cardiovascular Health Study (CHS)2,7 
 
Framingham Heart Study (FHS)2,8 
 
Johns Hopkins Genetic Study of Atherosclerosis Risk (GeneSTAR)9–11 
 
Health, Aging, and Body Composition  (HealthABC)9,12 
 
Invecchiare in Chianti Study (InCHIANTI)5 
 
PROspective Study of Pravastatin in the Elderly at Risk (PROSPER/PHASE)13 
 
Rotterdam Study I (RS-I)2,14 
 
Rotterdam Study II (RS-II)14 
 
Rotterdam Study III (RS-III)14 
 
 
East-Asian Ancestry Cohorts 
 
The BioBank Japan Project  (RIKEN)15,16 
 
Asian Genetic Epidemiology Network (AGEN)17,18 
 
 
African-American  Ancestry  Cohorts 
 
Atherosclerosis Risk in Communities Study (ARIC)3,12,19 
 
Jackson Heart Study (JHS)12,19,20 
 
Coronary Artery Risk Development in Young Adults  (CARDIA)6,12,19 
 
Cardiovascular Health Study  (CHS)7 
 
Johns Hopkins Genetic Study of Atherosclerosis Risk  (GeneSTAR) 9–11 Page  2
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Health, Aging, and Body Composition  (HealthABC)9,12 
 




Replication CohortsGutenberg Health Study (GHS)22 
 
 Genes and Blood-Clotting Study (GBC)23 
 
 Netherlands Epidemiology of Obesity Study  (NEO)24 
 
 JUPITER Trial25 
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Supplemental Methods and Results 
Additional Human Replication Findings 
The discovery and replication results were meta-analysed separately for the EUR and AFR cohorts in 
METAL and with RE2, and as a further step, the combined METAL results were further meta-analysed with 
the EAS discovery data using METAL,MANTRA and RE2 methods. (Table S5). 
In both the replication and discovery samples, we verified the allele directions in the original input files to 
address the question whether allele flipping could account for the RBPMS finding for MCH. In our results 
rs2979489 only became genome-wide significant in the trans-ethnic meta-analysis; the individual ethnic-
specific results were not significant. We checked the allele frequencies in several 1000G panels. In all cases 
A was the most common allele and G the rarest, as is the case in our HapMap analyses. 
Pleiotropy analysis   
To further relate these findings in the rbpms gene family back to the human association data, we evaluated 
RBPMS in WBC traits and RBPMS2 in our RBC analyses and WBC traits. The purpose of this analysis was 
to explore possible pleiotropy which might suggest effects on an earlier hematopoietic progenitor cell. 
Variants in the RBPMS and RBPMS2 gene regions (+/- 50kb from exon borders) showed no association with 
WBC traits in a trans-ethnic analysis of the same cohorts.26  Further, there was no evidence of association 
with erythrocyte traits in the RBPMS2 region. Therefore, while there may be evidence of a functional class 
effect of the rbpms genes in the zebrafish experimental data, the human association data suggest that 
genetic variation in the RBPMS locus specifically influences erythrocyte traits in humans and that RBPMS is 
likely the true causal gene underlying this association. 
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-log P value plots and varLD plots 
Regional association plots for loci identified by our trans-ethnic analysis. For each trait-locus identified in the 
MANTRA analyses, including the novel and previously known loci, we have plotted the individual ethnicity-
specific meta-analysis (METAL) results, the trans-ethnic fixed effects meta-analysis (METAL) and the 
Bayesian meta-analysis (MANTRA) results with SNPs colored according to the credible interval set for that 
region. Also shown for each region is the pair-wise LD correlation (varLD) and RNA expression of genes 




Index for Figure S1
trait Region chr cyto Index SNP Total_gene Page
Hct 1 2 2p21 rs4953318 PRKCE 10
Hct 2 2 2q21 rs6430549 ACMSD 11
Hct 3 4 4q12 rs218237 KIT 12
Hct 4 4 4q21 rs1398018 SHROOM3 13
Hct 5 6 6p22 rs1800562 HFE 14
Hct 6 6 6q23 rs9399137 HBS1L 15
Hct 7 7 7q22 rs2075672 ACTL6B 16
Hct 8 7 7q31 rs2299433 MET 17
Hct 9 7 7q36 rs10224210 PRKAG2 18
Hct 10 9 9q34 rs495828 ABO 19
Hct 11 10 10q21 rs16926246 HK1 20
Hct 12 12 12q24 rs3184504 SH2B3 21
Hct 13 15 15q24 rs4886755 NRG4 22
Hct 14 17 17q21 rs241030 CRHR1 23
Hct 15 22 22q12 rs2413450 TMPRSS6 24
Hct 16 22 22q13 rs5765524 FBLN1 25
Hb 1 2 2p21 rs4953318 PRKCE 27
Hb 2 3 3q29 rs12632706 TFRC 28
Hb 3 4 4q12 rs170117 KIT 29
Hb 4 6 6p22 rs1800562 HFE 30
Hb 5 6 6p21 rs412657 NOTCH4 31
Hb 6 7 7q22 rs1617640 EPO 32
Hb 7 7 7q31 rs2299433 MET 33
Hb 8 7 7q36 rs10480299 PRKAG2 34
Hb 9 9 9q34 rs495828 ABO 35
Hb 10 10 10q21 rs16926246 HK1 36
Hb 11 12 12q24 rs11066301 PTPN11 37
Hb 12 15 15q24 rs4886755 NRG4 38
Hb 13 16 16p13 rs2562181 MPG 39
Hb 14 17 17q21 rs241030 CRHR1 40
Hb 15 22 22q12 rs4820268 TMPRSS6 41
MCHC 1 1 1q23 rs2479868 SPTA1 43
MCHC 2 6 6p22 rs198846 HIST1H1T 44
MCHC 3 6 6q23 rs9376090 HBS1L 45
MCHC 4 8 8p11 rs4737009 ANK1 46
MCHC 5 12 12q24 rs671 NA 47
MCHC 6 16 16p13 rs7197554 C16orf35 48
MCHC 7 16 16q24 rs2608604 CDT1 49
MCHC 8 22 22q12 rs2413450 TMPRSS6 50
MCH 1 1 1q31 rs12127588 PTPRC 52
MCH 2 2 2p16 rs13019832 BCL11A 53
MCH 3 3 3p24 rs2060597 PLCL2 54
MCH 4 3 3p24 rs1505307 THRB 55
MCH 5 3 3q23 rs6791816 ATR 56
MCH 6 3 3q29 rs9859401 TFRC 57
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MCH 7 4 4q12 rs218237 KIT 58
MCH 8 5 5p15 rs2736100 TERT 59
MCH 9 6 6p22 rs1800562 HFE 60
MCH 10 6 6p21 rs9349205 CCND3 61
MCH 11 6 6q21 rs9400273 CCDC162P/CD164 62
MCH 12 6 6q23 rs7776054 HBS1L 63
MCH 13 6 6q24 rs592423 CITED2/LOC655434 64
MCH 14 7 7p12 rs12669559 IKZF1 65
MCH 15 7 7q22 rs12532878 MOSPD3 66
MCH 16 8 8p21 rs2076940 XPO7 67
MCH 17 8 8p12 rs2979489 RBPMS 68
MCH 18 9 9p24 rs10758656 RCL1/MIR101-2 69
MCH 19 10 10q11 rs11239550 08-mrt 70
MCH 20 10 10q11 rs17720193 NA 71
MCH 21 12 12p13 rs7309743 CCND2 72
MCH 22 12 12q24 rs2074356 NA 73
MCH 23 14 14q23 rs7155454 FNTB/MIR4706 74
MCH 24 15 15q22 rs7165102 C15orf44 75
MCH 25 16 16p13 rs1122794 ITFG3 76
MCH 26 17 17q11 rs9892942 ERAL1 77
MCH 27 19 19p13 rs8887 KIAA1881/PLIN4 78
MCH 28 19 19p13 rs2242517 GCDH 79
MCH 29 20 20q13 rs737092 RBM38 80
MCH 30 22 22q12 rs2413450 TMPRSS6 81
MCV 1 1 1q23 rs12041363 OR10R2 83
MCV 2 1 1q31 rs1036332 PTPRC/LOC100131234 84
MCV 3 1 1q44 rs3811444 TRIM58 85
MCV 4 2 2p25 rs10929547 ID2 86
MCV 5 2 2p16 rs13027161 BCL11A/MIR4432 87
MCV 6 3 3p24 rs9821630 PLCL2 88
MCV 7 3 3p24 rs1505307 THRB 89
MCV 8 3 3q23 rs6780250 ATR 90
MCV 9 3 3q29 rs3893275 ZDHHC19 91
MCV 10 4 4q12 rs218237 KIT 92
MCV 11 5 5p15 rs2736100 TERT 93
MCV 12 6 6p22 rs198833 HIST1H1T 94
MCV 13 6 6p21 rs9349205 CCND3 95
MCV 14 6 6q21 rs9374080 CD164/CCDC162P 96
MCV 15 6 6q23 rs7776054 HBS1L 97
MCV 16 6 6q24 rs592423 CITED2/LOC645434 98
MCV 17 6 6q26 rs381500 QKI 99
MCV 18 7 7p12 rs12718598 IKZF1 100
MCV 19 7 7q22 rs7385804 TFR2 101
MCV 20 8 8p21 rs10503716 XPO7 102
MCV 21 8 8p12 rs2979489 RBPMS 103
MCV 22 9 9p24 rs10758658 RCL1/MIR101-2 104
MCV 23 9 9q34 rs8176749 ABO 105
MCV 24 10 10q11 rs963029 08-mrt 106
MCV 25 12 12p13 rs11611647 CCND2 107
MCV 26 12 12q24 rs2074356 NA 108
MCV 27 14 14q23 rs726668 MAXMIR4706 109
MCV 28 15 15q22 rs7176565 DENND4A/MIR4511 110
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MCV 29 16 16p13 rs13336641 NA 111
MCV 30 17 17q11 rs12325788 TRAF4 112
MCV 31 18 18q21 rs9949494 C18orf25 113
MCV 32 19 19p13 rs8887 KIAA1881/PLIN4 114
MCV 33 19 19p13 rs9384 GCDH 115
MCV 34 20 20q11 rs6121246 FKHL18/FOXS1 116
MCV 35 20 20q13 rs737092 RBM38 117
MCV 36 22 22q11 rs4820091 UBE2L3 118
MCV 37 22 22q12 rs5754115 FBXO7 119
MCV 38 22 22q12 rs2413450 TMPRSS6 120
MCV 39 22 22q13 rs140522 LOC440836/ODF3B 121
RBC 1 2 2p21 rs4952800 PRKCE 123
RBC 2 4 4p14 rs3860068 TMEM156 124
RBC 3 4 4q12 rs218237 KIT 125
RBC 4 6 6p21 rs9349205 CCND3 126
RBC 5 6 6q21 rs9400273 CD164/CCDC162P 127
RBC 6 6 6q23 rs9376090 HBS1L 128
RBC 7 6 6q24 rs592423 CITED2/LOC645434 129
RBC 8 7 7q22 rs2075672 ACTL6B 130
RBC 9 9 9p24 rs10758656 RCL1/MIR101-2 131
RBC 10 9 9q34 rs579459 ABO 132
RBC 11 12 12p13 rs7309743 CCND2 133
RBC 12 16 16p13 rs13339636 NA 134
RBC 13 17 17q21 rs2732706 LRRC37A 135
RBC 14 19 19p13 rs17706531 GCDH 136









































































































































Van Rooij et al. - Transethnic Erythrocyte GWAS 
Supplemental References 
1. Harris, T. B. et al. Age, Gene/Environment Susceptibility-Reykjavik Study: multidisciplinary applied phenomics. Am.
J. Epidemiol. 165, 1076–1087 (2007). 
2. Ganesh, S. K. et al. Multiple loci influence erythrocyte phenotypes in the CHARGE Consortium. Nat. Genet. 41,
1191–1198 (2009). 
3. The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. The ARIC investigators. PMID:
2646917. Am. J. Epidemiol. 129, 687–702 (1989). 
4. Schmidt, R. et al. Assessment of cerebrovascular risk profiles in healthy persons: definition of research goals and
the Austrian Stroke Prevention Study (ASPS). Neuroepidemiology 13, 308–313 (1994). 
5. Nalls, M. A. et al. Multiple Loci Are Associated with White Blood Cell Phenotypes. PLoS Genet 7, e1002113 (2011).
6. Friedman, G. D. et al. CARDIA: study design, recruitment, and some characteristics of the examined subjects. J. Clin.
Epidemiol. 41, 1105–1116 (1988). 
7. Fried, L. P. et al. The Cardiovascular Health Study: design and rationale. PMID:1669507. Ann. Epidemiol. 1, 263–276
(1991). 
8. Feinleib, M., Kannel, W. B., Garrison, R. J., McNamara, P. M. & Castelli, W. P. The Framingham Offspring Study.
Design and preliminary data. PMID: 1208363. Prev. Med. 4, 518–525 (1975). 
9. Qayyum, R. et al. A Meta-Analysis and Genome-Wide Association Study of Platelet Count and Mean Platelet
Volume in African Americans. PLoS Genet 8, e1002491 (2012). 
10. Vaidya, D. et al. Coronary Artery Disease Incidence Over 10 Years in Siblings of Patients with Premature
Coronary Artery Disease. Am. J. Cardiol. 100, 1410–1415 (2007). 
11. Becker DM, Segal J, Vaidya D & et al. SEx differences in platelet reactivity and response to low-dose aspirin
therapy. JAMA 295, 1420–1427 (2006). 
12. Reiner, A. P. et al. Genome-Wide Association Study of White Blood Cell Count in 16,388 African Americans: the
Continental Origins and Genetic Epidemiology Network (COGENT). PLoS Genet 7, e1002108 (2011). 
13. Shepherd, J. et al. The design of a prospective study of Pravastatin in the Elderly at Risk (PROSPER). PROSPER
Study Group. PROspective Study of Pravastatin in the Elderly at Risk. Am. J. Cardiol. 84, 1192–1197 (1999). 
Page  138
Van Rooij et al. - Transethnic Erythrocyte GWAS 
14. Hofman, A. et al. The Rotterdam Study: 2016 objectives and design update. Eur. J. Epidemiol. 30, 661–708
(2015). 
15. Nakamura, Y. The BioBank Japan Project. Clin. Adv. Hematol. Oncol. HO 5, 696–697 (2007).
16. Okada, Y. et al. Identification of Nine Novel Loci Associated with White Blood Cell Subtypes in a Japanese
Population. PLoS Genet 7, e1002067 (2011). 
17. Liao, W.-L. et al. Gene polymorphisms of adiponectin and leptin receptor are associated with early onset of
type 2 diabetes mellitus in the Taiwanese population. Int. J. Obes. 36, 790–796 (2012). 
18. Jo, J. et al. Prediction of Colorectal Cancer Risk Using a Genetic Risk Score: The Korean Cancer Prevention
Study-II (KCPS-II). Genomics Inform. 10, 175–183 (2012). 
19. Chen, Z. et al. Genome-wide association analysis of red blood cell traits in African Americans: the COGENT
Network. Hum. Mol. Genet. 22, 2529–2538 (2013). 
20. Taylor, H. A. et al. Toward resolution of cardiovascular health disparities in African Americans: design and
methods of the Jackson Heart Study. Ethn. Dis. 15, S6–4–17 (2005). 
21. Design of the Women’s Health Initiative clinical trial and observational study. The Women’s Health Initiative
Study Group. Control. Clin. Trials 19, 61–109 (1998). 
22. Wild, D. P. S. et al. Die Gutenberg Gesundheitsstudie. Bundesgesundheitsblatt - Gesundheitsforschung -
Gesundheitsschutz 55, 824–830 (2012). 
23. Desch, K. C. et al. Linkage analysis identifies a locus for plasma von Willebrand factor undetected by genome-
wide association. Proc. Natl. Acad. Sci. U. S. A. 110, 588–593 (2013). 
24. Mutsert, R. de et al. The Netherlands Epidemiology of Obesity (NEO) study: study design and data collection.
Eur. J. Epidemiol. 28, 513–523 (2013). 
25. Ridker, P. M. Rosuvastatin in the Primary Prevention of Cardiovascular Disease Among Patients With Low
Levels of Low-Density Lipoprotein Cholesterol and Elevated High-Sensitivity C-Reactive Protein Rationale and 
Design of the JUPITER Trial. Circulation 108, 2292–2297 (2003). 
26. Keller, M. F. et al. Trans-ethnic meta-analysis of white blood cell phenotypes. Hum. Mol. Genet. ddu401
(2014). doi:10.1093/hmg/ddu401 
27. Watkins, N. A. et al. A HaemAtlas: characterizing gene expression in differentiated human blood cells. Blood
113, e1–e9 (2009). 
Page  139
Acknowledgements   
   Funding for Age, Gene/ Environment Susceptibility Reykjavik Study (AGES)was made 
possible by NIA/NIH contract AG000932-2 (2009) Characterization of Normal Genomic 
Variability. The Age, Gene/ Environment Susceptibility Reykjavik Study is funded by NIH 
contract N01-AG-12100, the NIA Intramural Research Program, Hjartavernd (the Icelandic 
Heart Association) and the Althingi (the Icelandic  Parliament).   
   Atherosclerosis Risk in Communities Study is carried out as a collaborative study supported 
by National Heart, Lung, and Blood Institute contracts (HHSN268201100005C, 
HHSN268201100006C, HHSN268201100007C, HHSN268201100008C, 
HHSN268201100009C, HHSN268201100010C, HHSN268201100011C, and 
HHSN268201100012C), R01HL087641, R01HL59367 and R01HL086694; National Human 
Genome Research Institute contract U01HG004402; and National Institutes of Health contract 
HHSN268200625226C. The authors thank the staff and participants of the ARIC study for their 
important contributions. Infrastructure was partly supported by Grant Number UL1RR025005, a 
component of the National Institutes of Health and NIH Roadmap for Medical Research. 
   Cardiovascular Health Study: This CHS research was supported by NHLBI contracts 
HHSN268201200036C, HHSN268200800007C, N01HC55222, N01HC85079, N01HC85080, 
N01HC85081, N01HC85082, N01HC85083, N01HC85086; and NHLBI grants U01HL080295, 
R01HL087652, R01HL105756, R01HL103612, and R01HL120393 with additional contribution 
from the National Institute of Neurological Disorders and Stroke (NINDS). Additional support 
was provided through R01AG023629 from the National Institute on Aging (NIA). A full list of 
principal CHS investigators and institutions can be found at CHS-NHLBI.org. 
Page  140
   The provision of genotyping data was supported in part by the National Center for Advancing 
Translational Sciences, CTSI grant UL1TR000124, and the National Institute of Diabetes and 
Digestive and Kidney Disease Diabetes Research Center (DRC) grant DK063491 to the 
Southern California Diabetes Endocrinology Research Center. 
   The content is solely the responsibility of the authors and does not necessarily represent the 
official views of the National Institutes of Health. 
   The  National  Heart,  Lung, and  Blood  Institute’s  Framingham  Heart  Study  is  a  joint 
project of the National Institutes of Health and Boston University  School  of  Medicine  and  was  
supported  by  the  National Heart,  Lung,  and  Blood  Institute’s  Framingham  Heart  Study 
(contract No. N01-HC-25195) and its contract with Affymetrix for genotyping services (contract 
No. N02-HL-6-4278). Analyses reflect the efforts and resource development from the 
Framingham  Heart  Study  investigators  participating  in  the  SNP Health  Association  
Resource  (SHARe)  project.  A  portion  of this  research  was  conducted  using  the  Linux  
Cluster  for Genetic  Analysis  (LinGA-II)  funded  by  the  Robert  Dawson Evans  Endowment  
of  the  Department  of  Medicine  at  the Boston  University  School  of  Medicine  and  Boston  
Medical Center. The views expressed in this manuscript are those of the authors and do not 
necessarily represent the views of the National Heart, Lung, and Blood Institute; the National 
Institutes of Health; or the U.S. Department of Health and Human Services. 
   The Health ABC Study was supported in part by the Intramural Research Program of the NIH, 
National Institute on Aging, NIA contracts N01AG62101, N01AG62103 and N01AG 62106. The 
GWAS was funded by NIA grant 1R01AG032098- 01A1 to Wake Forest University Health 
Sciences and genotyp- ing services were provided by the Center for Inherited Disease 
Research (CIDR). CIDR is fully funded through a federal con- tract  from  the  National  
Page  141
Institutes  of  Health  to  The  Johns Hopkins University (contract number 
HHSN268200782096C).  
   The PROSPER study was supported by an investigator initiated grant obtained from Bristol-
Myers Squibb. Prof. Dr. J. W. Jukema is an Established Clinical Investigator of the Netherlands 
Heart Foundation (grant 2001 D 032). Support for genotyping was provided by the seventh 
framework program of the European commission (grant 223004) and by the Netherlands 
Genomics Initiative (Netherlands Consortium for Healthy Aging grant 050-060-810). 
   The InChianti Study was supported as a ‘targeted project’ (ICS 110.1RS97.71) by the Italian 
Ministry of Health, by the US Na- tional  Institute  on  Aging  (contracts  N01-AG-916413,  N01- 
AG-821336,  263  MD  9164  13  and  263  MD  821336)  and  in part by the Intramural 
Research Program, National Institute on Aging, National Institutes of Health, USA.  
   The generation and management of GWAS genotype data for the Rotterdam Study (RS I, RS 
II, RS III) was executed by the Human Genotyping Facility of the Genetic Laboratory of the 
Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands. The GWAS 
datasets are supported by the Netherlands Organisation of Scientific Research NWO 
Investments (nr. 175.010.2005.011, 911-03-012), the Genetic Laboratory of the Department of 
Internal Medicine, Erasmus MC, the Research Institute for Diseases in the Elderly (014-93-015; 
RIDE2), the Netherlands Genomics Initiative (NGI)/Netherlands Organisation for Scientific 
Research (NWO) Netherlands Consortium for Healthy Aging (NCHA), project nr. 050-060-810. 
We thank Pascal Arp, Mila Jhamai, Marijn Verkerk, Lizbeth Herrera and Marjolein Peters, MSc, 
and Carolina Medina-Gomez, MSc, for their help in creating the GWAS database, and Karol 
Estrada, PhD, Yurii Aulchenko, PhD, and Carolina Medina-Gomez, MSc, for the creation and 
analysis of imputed data. The Rotterdam Study is funded by Erasmus Medical Center and 
Erasmus University, Rotterdam, Netherlands Organization for the Health Research and 
Page  142
Development (ZonMw), the Research Institute for Diseases in the Elderly (RIDE), the Ministry of 
Education, Culture and Science, the Ministry for Health, Welfare and Sports, the European 
Commission (DG XII), and the Municipality of Rotterdam. The authors are grateful to the study 
participants, the staff from the Rotterdam Study and the participating general practitioners and 
pharmacists.  
   Funding for COGENT was obtained through the Broad Institute (N01-HC- 65226) to  create  
this  genotype/phenotype  database  for  wide dissemination to the biomedical research 
community.  
   Coronary  Artery  Risk  in  Young  Adults (CARDIA): University of Alabama at Birmingham 
(N01-HC- 48047),  University  of  Minnesota  (N01-HC-48048),  North- western   University    
(N01-HC-48049),   Kaiser   Foundation Research Institute (N01-HC-48050), University of 
Alabama at Birmingham  (N01-HC-95095),  Tufts-New  England  Medical Center  (N01-HC-
45204),  Wake  Forest  University  (N01-HC- 45205), Harbor-UCLA Research and Education 
Institute (N01- HC-05187),  University  of  California,  Irvine  (N01-HC-45134 and  N01-HC-
95100).   
   Jackson Heart  Study   (JHS):  Contracts HHSN268201300046C, HHSN268201300047C, 
HHSN268201300048C, HHSN268201300049C, HHSN268201300050C from the National 
Heart, Lung, and Blood Institute and the National Institute on Minority Health and Health 
Disparities. .  
   Healthy Aging  in  Neighborhoods  of  Diversity  across  the  Life  Span Study (HANDLS): This 
research was supported by the Intramural Research Program of the NIH, National Institute on 
Aging and the National Center on Minority Health and Health Disparities (intra- mural project # 
Z01-AG000513 and human subjects protocol # 2009-149).  
Page  143
   Health ABC: This research was supported by NIA contracts N01AG62101, N01AG62103 and 
N01AG62106. The GWAS  was  funded  by  NIA  grant  1R01AG032098-01A1  to Wake Forest 
University Health Sciences and genotyping services were  provided  by  the  Center  for  
Inherited  Disease  Research (CIDR). CIDR is fully funded through a federal contract from the 
National Institutes of Health to The Johns Hopkins University (contract  number  
HHSN268200782096C).  This  research  was supported  in  part  by  the  Intramural  Research  
Program  of  the NIH,  National  Institute  on  Aging.   
   GeneSTAR: This research was supported by the National Heart, Lung, and  Blood  Institute  
(NHLBI)  through  the  PROGENI  (U01 HL72518) and STAMPEED (R01 HL087698-01) 
consortia. Additional support was provided by grants from the NIH/National In- stitute of Nursing 
Research (R01 NR08153) and the NIH/National Center for Research Resources (M01-
RR000052) to the Johns Hopkins General  Clinical  Research  Center.   
   Women’s Health Initiative (WHI):  The WHI program is funded by the National Heart, Lung, 
and Blood Institute, National Institutes of Health, U.S. Department of Health and Human 
Services through contracts HHSN268201100046C, HHSN268201100001C, 
HHSN268201100002C, HHSN268201100003C, HHSN268201100004C, and 
HHSN271201100004C..   
Funding for RIKEN and the BioBank Japan Project was supported by Ministry of Education, 
Culture, Sports, Science and Technology, Japan.  
 
   The Gutenberg Health Study is funded through the government of Rhineland-Palatinate 
(„Stiftung Rheinland-Pfalz für Innovation“, contract AZ 961-386261/733), the research programs 
“Wissen schafft Zukunft” and “Center for Translational Vascular Biology (CTVB)” of the 
Johannes Gutenberg-University of Mainz, and its contract with Boehringer Ingelheim and 
Page  144
PHILIPS Medical Systems, including an unrestricted grant for the Gutenberg Health Study. VG 
PSW are funded by the Federal Ministry of Education and Research (BMBF 01EO1503). TZ 
and PSW are PIs of the German Center for Cardiovascular Research. The remaining authors 
have nothing to declare. 
   The Genes and Blood Clotting Study was supported by the National Institute of Health grants 
R37HL039693 (K.C.D., D.G.) and RO1HL112642 (A.B.O., K.C.D.,J.Z.L., D.G.).  Additionally, 
David Ginsburg is a Howard Hughes Medical Institute investigator.   
   The authors of the NEO study thank all individuals who participated in the Netherlands 
Epidemiology in Obesity study, all participating general practitioners for inviting eligible 
participants and all research nurses for collection of the data. We thank the NEO study group, 
Pat van Beelen, Petra Noordijk and Ingeborg de Jonge for the coordination, lab and data 
management of the NEO study. The genotyping in the NEO study was supported by the Centre 
National de Génotypage (Paris, France), headed by Jean-Francois Deleuze. The NEO study is 
supported by the participating Departments, the Division and the Board of Directors of the 
Leiden University Medical Center, and by the Leiden University, Research Profile Area Vascular 
and Regenerative Medicine. Dennis Mook-Kanamori is supported by Dutch Science 
Organization (ZonMW-VENI Grant 916.14.023). 
   The JUPITER trial and the genotyping were supported by AstraZeneca. 
   The development of the software package MANTRA was performed by Andrew P. Morris, a 
Wellcome Trust Senior Research Fellow in Basic Biomedical Science (grant numbers 
WT098017, WT090532 and WT064890).  
   Professor Luanne L. Peters (LLP) is supported by NIH grants HL085480 and DK100692, and 
by National Cancer Institute Award P30CA034196 to the Jackson Laboratory. Santhi.K.Ganesh 
is supported by the Doris Duke Charitable Foundation and NIH HL122684 grants. Yukinori 
Page  145
Okada was supported by the Japan Society for the Promotion of Science (JSPS) KAKENHI 
grant numbers 15H05911, 15H05670, 15K14429, the Japan Science and Technology Agency 
(JST), Mochida Memorial Foundation for Medical and Pharmaceutical Research, Takeda 
Science Foundation, Gout Research Foundation, the Tokyo Biochemical Research Foundation, 
and the Japan Rheumatism Foundation.  Robert J. Klein was supported by grant number U01 
HG007033 from NHGRI.  
 
   The funders had no role in study design, data collection and analysis, decision to publish or 
preparation of the manuscript.  
 
Page  146
